These have not been systemically examined in SMA, and we hypothesized that CSF proteins involved in inflammation and neuronal activity may better correlate with individual response to SMN1 enhancing therapies than NfL [8–10]. Here, SMN1 is linked to proximal spinal muscular atrophy.